NeoVax turns tumour mutations into a personalised vaccine. A phase 1 study with nivolumab in ovarian cancer found the approach feasible and acceptably safe.
Trending
- The Telescope Survey That Found Saturn 128 More Moons
- NeoVax Plus Nivolumab: Inside the Ovarian Vaccine Study
- How Technology Is Changing Breast Cancer Detection
- AI Data Centers: Why the Spending Math Is Changing Fast
- Understanding Verification Requests
- On-Device AI Is Quietly Becoming the Smartphone Feature That Matters
- How CPAs Simplify Complex Financial Statements
- How Accounting Firms Provide Strategic Guidance To Executives